Roivant Sciences Ltd.

Roivant Sciences Ltd. reported a net loss attributable to the company of $(189.8) million, or $(0.26) per share, for the three months ended June 30, 2026, showing an improvement in EPS compared to the prior year. Revenue decreased to $1.4 million, while research and development expenses significantly increased to $202.0 million. The company maintained a strong liquidity position with $3.8 billion in cash, cash equivalents, and marketable securities.

Roivant Sciences Ltd. reported a net loss of $290.6 million for the first fiscal quarter ended June 30, 2026, an increase from $273.9 million in the prior year. The company received an initial $950 million payment from Moderna in July 2026 as part of a $2.25 billion patent infringement settlement, with an additional $1.3 billion contingent on a favorable appeal resolution. Roivant also provided updates on its clinical pipeline, including progress for brepocitinib, IMVT-1402, and mosliciguat, and initiated new international lawsuits against Pfizer and BioNTech.

Roivant Sciences Ltd. announced its 2026 Annual General Meeting of Shareholders (AGM) will take place on September 16, 2026, in London. Key proposals for shareholder vote include the election of two Class II directors, Daniel Gold and Meghan FitzGerald, and the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending March 31, 2027. Additionally, shareholders will cast a non-binding advisory vote on executive compensation. The record date for shareholders entitled to vote is July 23, 2026.

Roivant Sciences Ltd. announced significant progress in its pipeline and a major legal settlement. The FDA accepted brepocitinib's New Drug Application (NDA) for dermatomyositis with Priority Review, setting a target action date in 3Q 2026, following positive Phase 3 VALOR study data. The company also reported a $2.25 billion global settlement with Moderna, resolving patent infringement litigation, with $950 million payable in July 2026. Additionally, Roivant completed a $550 million financing for Immunovant, discontinued batoclimab development to focus on IMVT-1402, and expects several key clinical trial data readouts in 2H 2026 and 2027-2028.

Roivant Sciences reported its financial results for the fourth quarter and fiscal year ended March 31, 2026, highlighted by a significant $2.25 billion global settlement with Moderna. The company achieved income from continuing operations, net of tax, of $355.7 million for the quarter, largely driven by the litigation settlement gain. Roivant also provided positive business updates, including strong clinical trial data for IMVT-1402, Breakthrough Therapy Designation for brepocitinib, and several upcoming commercial launches and clinical readouts, while maintaining a strong cash position of $4.3 billion.

Roivant Sciences announced a $2.25 billion global settlement with Moderna, resolving all pending patent-infringement litigation, with $950 million payable in July 2026. The company also reported positive Period 1 data for IMVT-1402 in difficult-to-treat rheumatoid arthritis, showing a 72.7% ACR20 response rate. Additionally, brepocitinib received Breakthrough Therapy Designation for cutaneous sarcoidosis and is expected to launch commercially in dermatomyositis by September 2026. Roivant ended the fiscal year with $4.3 billion in cash, cash equivalents, and marketable securities, while discontinuing batoclimab development.